VERY-RARE CANCERSkin CancerWHO 5th Edition Classification

Merkel Cell Carcinoma

Very Rare Malignancy (1–5 cases per 1,000,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

An aggressive neuroendocrine skin cancer with two distinct causes: integration of Merkel cell polyomavirus, which accounts for most cases, and cumulative ultraviolet damage in the remainder. It is far more likely than melanoma to have spread to lymph nodes at presentation despite a small and unremarkable-looking primary.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • The AEIOU features - Asymptomatic, Expanding rapidly, Immunosuppressed, Older than 50, UV-exposed fair skin
Who It Affects

Older adults over 65, fair-skinned; markedly increased in immunosuppression

Annual Incidence

Approximately 0.7 per 100,000 per year and rising

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

A firm, painless, rapidly growing red or violet nodule on sun-exposed skin
Most often on the head, neck or forearm
Enlarged regional lymph nodes
Usually not ulcerated or itchy, which is why it is often dismissed as a cyst
Occasionally presents as nodal disease with no identifiable primary

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

Merkel cell polyomavirus (about 80%)High UV mutational burden in virus-negative diseaseRB1TP53CK20 dot-like positivity

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Wide local excision with sentinel lymph node biopsy - mandatory even for small lesions

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Adjuvant radiotherapy to the primary site and draining nodal basin

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Immune checkpoint inhibitors - avelumab, pembrolizumab, retifanlimab - for advanced disease

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Chemotherapy (platinum-etoposide) where immunotherapy is contraindicated

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Reduction of immunosuppression where clinically possible

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Stage-dependent. Five-year survival is around 75% for localised disease but historically under 20% for metastatic disease - though checkpoint inhibitors have substantially improved this, with durable responses in a significant proportion of treated patients.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Neoadjuvant checkpoint blockade, combination immunotherapy for primary refractory disease, and MCPyV-specific T-cell therapies are the leading directions. Antibody titres to MCPyV oncoprotein are used for surveillance.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Merkel Cell Carcinoma

Browse All Oncologists

Dr. Paul Nghiem

Dermatologic Oncologist

20+ yrs exp

UW/Fred Hutch

Seattle, USA

Dermatologic OncologyMerkel Cell CarcinomaImmunotherapy
Vetted DirectoryConsult Specialist

Dr. Lee Soo Chin

Medical Oncologist

25+ yrs exp

NCIS

Singapore, Singapore

Medical OncologyMerkel Cell CarcinomaCheckpoint Inhibitors
Vetted DirectoryConsult Specialist

Prof. Dirk Schadendorf

Dermatologic Oncologist

30+ yrs exp

University Hospital Essen

Essen, Germany

Dermatologic OncologyMerkel Cell CarcinomaClinical Trials
Vetted DirectoryConsult Specialist

Dr. Nikhil Vasudev

Medical Oncologist

15+ yrs exp

Tata Memorial

Mumbai, India

Medical OncologyMerkel Cell CarcinomaRare Skin Cancers
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

very-rare

Angioimmunoblastic T-cell Lymphoma (AITL)

very-rare

Appendiceal Carcinoma

very-rare

Esthesioneuroblastoma

very-rare

Adenoid Cystic Carcinoma (ACC)

Independent Tumor Board Review

Facing a Diagnosis of Merkel Cell Carcinoma?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult